These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 23635093

  • 1. Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.
    Dons EM, Raimondi G, Zhang H, Zahorchak AF, Bhama JK, Lu L, Ezzelarab M, Ijzermans JN, Cooper DK, Thomson AW.
    Am J Transplant; 2013 Aug; 13(8):2169-78. PubMed ID: 23635093
    [Abstract] [Full Text] [Related]

  • 2. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
    Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, Shankara S, Roberts BL, Kaplan JM.
    PLoS One; 2012 Aug; 7(6):e39416. PubMed ID: 22761788
    [Abstract] [Full Text] [Related]

  • 3. Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys.
    Marco MR, Dons EM, van der Windt DJ, Bhama JK, Lu LT, Zahorchak AF, Lakkis FG, Cooper DK, Ezzelarab MB, Thomson AW.
    Transpl Immunol; 2013 Dec; 29(1-4):88-98. PubMed ID: 24120957
    [Abstract] [Full Text] [Related]

  • 4. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
    Lee F, Luevano M, Veys P, Yong K, Madrigal A, Shaw BE, Saudemont A.
    PLoS One; 2014 Dec; 9(7):e103254. PubMed ID: 25050704
    [Abstract] [Full Text] [Related]

  • 5. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS.
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [Abstract] [Full Text] [Related]

  • 6. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW.
    Blood; 2003 Feb 15; 101(4):1422-9. PubMed ID: 12393688
    [Abstract] [Full Text] [Related]

  • 7. Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.
    Ambrose LR, Morel AS, Warrens AN.
    Blood; 2009 Oct 01; 114(14):3052-5. PubMed ID: 19638623
    [Abstract] [Full Text] [Related]

  • 8. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.
    Havari E, Turner MJ, Campos-Rivera J, Shankara S, Nguyen TH, Roberts B, Siders W, Kaplan JM.
    Immunology; 2014 Jan 01; 141(1):123-31. PubMed ID: 24116901
    [Abstract] [Full Text] [Related]

  • 9. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.
    Siders WM, Shields J, Garron C, Hu Y, Boutin P, Shankara S, Weber W, Roberts B, Kaplan JM.
    Leuk Lymphoma; 2010 Jul 01; 51(7):1293-304. PubMed ID: 20377308
    [Abstract] [Full Text] [Related]

  • 10. Effect of alemtuzumab on neoplastic B cells.
    Golay J, Manganini M, Rambaldi A, Introna M.
    Haematologica; 2004 Dec 01; 89(12):1476-83. PubMed ID: 15590398
    [Abstract] [Full Text] [Related]

  • 11. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA.
    Cancer Res; 2003 Oct 01; 63(19):6453-7. PubMed ID: 14559836
    [Abstract] [Full Text] [Related]

  • 12. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
    Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM.
    Immunology; 2009 Oct 01; 128(2):260-70. PubMed ID: 19740383
    [Abstract] [Full Text] [Related]

  • 13. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
    Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, Hale G, Alexander DR.
    Int Immunol; 2000 Apr 01; 12(4):505-16. PubMed ID: 10744652
    [Abstract] [Full Text] [Related]

  • 14. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
    Hotta R, Ohira M, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, Ricordi C, Vianna R, Ohdan H, Waldmann H, Tzakis AG, Nishida S.
    PLoS One; 2016 Apr 01; 11(8):e0161618. PubMed ID: 27560943
    [Abstract] [Full Text] [Related]

  • 15. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ, Clarke E, Blair A, Evely R, Hale G, Waldmann H, Brookes S, Pamphilon DH.
    Cytotherapy; 2000 Apr 01; 2(1):5-14. PubMed ID: 12042050
    [Abstract] [Full Text] [Related]

  • 16. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
    Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH.
    Blood; 2010 Dec 23; 116(26):5930-40. PubMed ID: 20844239
    [Abstract] [Full Text] [Related]

  • 17. Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys.
    Van Der Windt DJ, Smetanka C, Macedo C, He J, Lakomy R, Bottino R, Ekser B, Echeverri GJ, Metes D, Ijzermans JNM, Trucco M, Cooper DKC, Lakkis FG.
    Am J Transplant; 2010 Apr 23; 10(4):773-783. PubMed ID: 20420638
    [Abstract] [Full Text] [Related]

  • 18. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.
    Pulaski HL, Spahlinger G, Silva IA, McLean K, Kueck AS, Reynolds RK, Coukos G, Conejo-Garcia JR, Buckanovich RJ.
    J Transl Med; 2009 Jun 19; 7():49. PubMed ID: 19545375
    [Abstract] [Full Text] [Related]

  • 19. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
    Mone AP, Cheney C, Banks AL, Tridandapani S, Mehter N, Guster S, Lin T, Eisenbeis CF, Young DC, Byrd JC.
    Leukemia; 2006 Feb 19; 20(2):272-9. PubMed ID: 16341049
    [Abstract] [Full Text] [Related]

  • 20. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D.
    Leuk Res; 1998 Feb 19; 22(2):185-91. PubMed ID: 9593475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.